DrugPatentWatch Database Preview➤ Subscribe for complete access
« Back to Dashboard
Phentermine hydrochlorideis the generic ingredient in eleven branded drugs marketed by Teva, Glaxosmithkline, Ferndale Labs, Shire Richwood, Mast Mm, Abc Holding, Able, Aurolife Pharma Llc, Barr, Camall, Chartwell Rx, Duramed Pharms Barr, Elite Labs, Elite Labs Inc, Invagen Pharms, Ivax Pharms, Kvk Tech, Lannett, Lannett Co Inc, Nuvo Pharm, Sandoz, Sun Pharm Industries, Tg United Inc, Upsher Smith Labs, Usl Pharma, Vitarine, Watson Labs, Zydus Pharms, Citius Pharms, Avanthi Inc, Actavis Elizabeth, Kvk Tech Inc, Merro Pharm Usa, Novast Labs, Prinston Inc, Sandoz Inc, Sun Pharm Inds Inc, Solvay, and Vivus, and is included in one hundred NDAs. There are seven patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.
Phentermine hydrochloride has two patent family members in two countries.
There are seventeen drug master file entries for phentermine hydrochloride. Thirty suppliers are listed for this compound.
Summary for PHENTERMINE HYDROCHLORIDE
|Drug Master File Entries:||17|
|Finished Product Suppliers / Packagers:||30|
|Raw Ingredient (Bulk) Api Vendors:||36|
|Formulation / Manufacturing:||see details|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for PHENTERMINE HYDROCHLORIDE|
|What excipients (inactive ingredients) are in PHENTERMINE HYDROCHLORIDE?||PHENTERMINE HYDROCHLORIDE excipients list|
|DailyMed Link:||PHENTERMINE HYDROCHLORIDE at DailyMed|
Recent Clinical Trials for PHENTERMINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
|KVK-Tech, Inc.||Phase 4|
|HealthPartners Institute||Phase 4|
|The University of Texas Health Science Center, Houston||Phase 4|
Pharmacology for PHENTERMINE HYDROCHLORIDE
|Drug Class|| Sympathomimetic Amine Anorectic |
|Physiological Effect||Appetite Suppression |
Increased Sympathetic Activity
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Patent No.||Patent Expiration|
|Citius Pharms||SUPRENZA||phentermine hydrochloride||TABLET, ORALLY DISINTEGRATING;ORAL||202088-001||Jun 13, 2011||⤷ Try it Free||⤷ Try it Free|
|Citius Pharms||SUPRENZA||phentermine hydrochloride||TABLET, ORALLY DISINTEGRATING;ORAL||202088-002||Jun 13, 2011||⤷ Try it Free||⤷ Try it Free|
|Citius Pharms||SUPRENZA||phentermine hydrochloride||TABLET, ORALLY DISINTEGRATING;ORAL||202088-003||Mar 27, 2012||⤷ Try it Free||⤷ Try it Free|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>Patent No.||>Patent Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.